Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224263
Status:
COMPLETED
Last Update Posted:
2011-08-16
First Post:
2005-09-20
Brief Title:
Efficacy and Safety of Lingzhi in Patients With Early Parkinsons Disease
Sponsor:
Xuanwu Hospital Beijing
Organization:
Xuanwu Hospital Beijing
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinsons Disease Receiving Stable L-dopaDCI
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Lingzhi Ganoderma a widely used traditional Chinese Medicine is effective and safe in the treatment of Parkinsons disease when combined use with L-dopa
Detailed Description:
This study is to focus on the effects of Lingzhi on non-motor symptoms of Parkinsons diseases as the primary outcome and on delaying the disease progression using the delay start design as the secondary outcome measurement Two dosage groups and one placebo control group with total 360 subjects will be recruited The treatment is one year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None